CSL's Fluad Seems Headed For Post-Marketing Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Adjuvanted seasonal influenza vaccine should get accelerated approval but needs confirmatory trial to address imbalance in deaths following revaccination, FDA advisory committee says.